BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1074 related articles for article (PubMed ID: 14508836)

  • 61. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
    Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; Hart AA
    Surgery; 1994 Jan; 115(1):39-45. PubMed ID: 8284759
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
    Jakob J; von Rege I; Weiss C; Hohenberger P
    Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone.
    Denton JW; Dunham WK; Salter M; Urist MM; Balch CM
    Surg Gynecol Obstet; 1984 Jun; 158(6):545-51. PubMed ID: 6587604
    [TBL] [Abstract][Full Text] [Related]  

  • 65. TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for modification of the perfusional schedule.
    Rossi CR; Foletto M; Mocellin S; Pilati PL; Campana L; Rubello D; Lise M
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):103-7. PubMed ID: 16767915
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
    Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
    Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
    Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
    Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma.
    Tsuchiya H; Yamamoto N; Asada N; Terasaki T; Kanazawa Y; Takanaka T; Nishijima H; Tomita K
    Anticancer Res; 2000; 20(3B):2137-43. PubMed ID: 10928167
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma.
    Menendez LR; Ahlmann ER; Savage K; Cluck M; Fedenko AN
    Clin Orthop Relat Res; 2007 Feb; 455():219-24. PubMed ID: 17016226
    [TBL] [Abstract][Full Text] [Related]  

  • 71. TNF dose reduction in isolated limb perfusion.
    Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
    Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Adjuvant radiation therapy for soft tissue sarcoma of the extremities: analysis of local control according to volume and dose].
    Milbéo Y; Kantor G; Laharie H; Lagarde P; Stoeckle E; Bonichon F; Thomas L; Brouste V; Bui BN
    Cancer Radiother; 2005 Sep; 9(5):293-303. PubMed ID: 16005654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
    van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Isolated limb perfusion for liposarcoma : Histopathological response and subgroup analysis after TNF melphalan-based ILP].
    Podleska LE; Schwindenhammer B; Grabellus F; Bauer S; Steinau HU; Taeger G
    Chirurg; 2017 May; 88(5):429-436. PubMed ID: 28083602
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases].
    Moureau-Zabotto L; Thomas L; Bui BN; Chevreau C; Stockle E; Martel P; Bonneviale P; Marques B; Coindre JM; Kantor G; Matsuda T; Delannes M
    Cancer Radiother; 2004 Oct; 8(5):279-87. PubMed ID: 15561593
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats.
    Manusama ER; Nooijen PT; Stavast J; de Wilt JH; Marquet RL; Eggermont AM
    J Surg Res; 1998 Aug; 78(2):169-75. PubMed ID: 9733636
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
    Bonvalot S; de Baere T; Mendiboure J; Paci A; Farace F; Drouard-Troalen L; Bonnet L; Hakime A; Bonniaud G; Raynard B; Israel P; Le Cesne A; Eggermont AM; Laplanche A; Muret J
    Ann Surg; 2012 Feb; 255(2):281-6. PubMed ID: 22241290
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.